Acquired factor VIII inhibitor.
Development of a circulating inhibitor of the coagulant activity of factor VIII is a rare event producing a clinical picture similar to that of classic hemophilia. A case of autoimmune factor VIII inhibitor has been presented. Although a hemostatic response was rapidly achieved with the infusion of factor IX concentrates, immunosuppressive therapy was initiated. The inhibitor disappeared in less than 20 days from the initiation of therapy.
Simpson
W G
WG
Department of Medicine, University of Kentucky College of Medicine, Lexington.
Neefe
J
J
Zang
J
J
Drosick
R
R
Kearns
R
R
D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D001778:Blood Coagulation Disorders / Q000188:drug therapy / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D005169:Factor VIII